Cargando…

The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis

BTG1 (B-cell translocation gene 1) may inhibit proliferation and cell cycle progression, induce differentiation, apoptosis, and anti-inflammatory activity. The goal of this study was to clarify the clinicopathological and prognostic significances of BTG1 mRNA expression and related signal pathways i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Hua-chuan, Xue, Hang, Zhang, Cong-yu, Shi, Kai-hang, Zhang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633688/
https://www.ncbi.nlm.nih.gov/pubmed/36339000
http://dx.doi.org/10.3389/fgene.2022.1006636
_version_ 1784824292976885760
author Zheng, Hua-chuan
Xue, Hang
Zhang, Cong-yu
Shi, Kai-hang
Zhang, Rui
author_facet Zheng, Hua-chuan
Xue, Hang
Zhang, Cong-yu
Shi, Kai-hang
Zhang, Rui
author_sort Zheng, Hua-chuan
collection PubMed
description BTG1 (B-cell translocation gene 1) may inhibit proliferation and cell cycle progression, induce differentiation, apoptosis, and anti-inflammatory activity. The goal of this study was to clarify the clinicopathological and prognostic significances of BTG1 mRNA expression and related signal pathways in cancers. Using the Oncomine, TCGA (the cancer genome atlas), xiantao, UALCAN (The University of ALabama at Birmingham Cancer data analysis Portal), and Kaplan-Meier plotter databases, we undertook a bioinformatics study of BTG1 mRNA expression in cancers. BTG1 expression was lower in gastric, lung, breast and ovarian cancer than normal tissue due to its promoter methylation, which was the opposite to BTG1 expression. BTG1 expression was positively correlated with dedifferentiation and histological grading of gastric cancer (p < 0.05), with squamous subtype and young age of lung cancer (p < 0.05), with infrequent lymph node metastasis, low TNM staging, young age, white race, infiltrative lobular subtype, Her2 negativity, favorable molecular subtyping, and no postmenopause status of breast cancer (p < 0.05), and with elder age, venous invasion, lymphatic invasion, and clinicopathological staging of ovarian cancer (p < 0.05). BTG1 expression was negatively correlated with favorable prognosis of gastric, lung or ovarian cancer patients, but the converse was true for breast cancer (p < 0.05). KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis showed that the top signal pathways included cytokine-cytokine receptor interaction, cell adhesion molecules, chemokine, immune cell receptor and NF (nuclear factor)-κB signal pathways in gastric and breast cancer. The top hub genes mainly contained CD (cluster of differentiation) antigens in gastric cancer, FGF (fibroblast growth factor)-FGFR (FGF receptor) in lung cancer, NADH (nicotinamide adenine dinucleotide): ubiquinone oxidoreductase in breast cancer, and ribosomal proteins in ovarian cancer. BTG1 expression might be employed as a potential marker to indicate carcinogenesis and subsequent progression, even prognosis.
format Online
Article
Text
id pubmed-9633688
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96336882022-11-05 The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis Zheng, Hua-chuan Xue, Hang Zhang, Cong-yu Shi, Kai-hang Zhang, Rui Front Genet Genetics BTG1 (B-cell translocation gene 1) may inhibit proliferation and cell cycle progression, induce differentiation, apoptosis, and anti-inflammatory activity. The goal of this study was to clarify the clinicopathological and prognostic significances of BTG1 mRNA expression and related signal pathways in cancers. Using the Oncomine, TCGA (the cancer genome atlas), xiantao, UALCAN (The University of ALabama at Birmingham Cancer data analysis Portal), and Kaplan-Meier plotter databases, we undertook a bioinformatics study of BTG1 mRNA expression in cancers. BTG1 expression was lower in gastric, lung, breast and ovarian cancer than normal tissue due to its promoter methylation, which was the opposite to BTG1 expression. BTG1 expression was positively correlated with dedifferentiation and histological grading of gastric cancer (p < 0.05), with squamous subtype and young age of lung cancer (p < 0.05), with infrequent lymph node metastasis, low TNM staging, young age, white race, infiltrative lobular subtype, Her2 negativity, favorable molecular subtyping, and no postmenopause status of breast cancer (p < 0.05), and with elder age, venous invasion, lymphatic invasion, and clinicopathological staging of ovarian cancer (p < 0.05). BTG1 expression was negatively correlated with favorable prognosis of gastric, lung or ovarian cancer patients, but the converse was true for breast cancer (p < 0.05). KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis showed that the top signal pathways included cytokine-cytokine receptor interaction, cell adhesion molecules, chemokine, immune cell receptor and NF (nuclear factor)-κB signal pathways in gastric and breast cancer. The top hub genes mainly contained CD (cluster of differentiation) antigens in gastric cancer, FGF (fibroblast growth factor)-FGFR (FGF receptor) in lung cancer, NADH (nicotinamide adenine dinucleotide): ubiquinone oxidoreductase in breast cancer, and ribosomal proteins in ovarian cancer. BTG1 expression might be employed as a potential marker to indicate carcinogenesis and subsequent progression, even prognosis. Frontiers Media S.A. 2022-10-21 /pmc/articles/PMC9633688/ /pubmed/36339000 http://dx.doi.org/10.3389/fgene.2022.1006636 Text en Copyright © 2022 Zheng, Xue, Zhang, Shi and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Zheng, Hua-chuan
Xue, Hang
Zhang, Cong-yu
Shi, Kai-hang
Zhang, Rui
The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis
title The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis
title_full The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis
title_fullStr The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis
title_full_unstemmed The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis
title_short The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis
title_sort roles of btg1 mrna expression in cancers: a bioinformatics analysis
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633688/
https://www.ncbi.nlm.nih.gov/pubmed/36339000
http://dx.doi.org/10.3389/fgene.2022.1006636
work_keys_str_mv AT zhenghuachuan therolesofbtg1mrnaexpressionincancersabioinformaticsanalysis
AT xuehang therolesofbtg1mrnaexpressionincancersabioinformaticsanalysis
AT zhangcongyu therolesofbtg1mrnaexpressionincancersabioinformaticsanalysis
AT shikaihang therolesofbtg1mrnaexpressionincancersabioinformaticsanalysis
AT zhangrui therolesofbtg1mrnaexpressionincancersabioinformaticsanalysis
AT zhenghuachuan rolesofbtg1mrnaexpressionincancersabioinformaticsanalysis
AT xuehang rolesofbtg1mrnaexpressionincancersabioinformaticsanalysis
AT zhangcongyu rolesofbtg1mrnaexpressionincancersabioinformaticsanalysis
AT shikaihang rolesofbtg1mrnaexpressionincancersabioinformaticsanalysis
AT zhangrui rolesofbtg1mrnaexpressionincancersabioinformaticsanalysis